Oncocross to co-develop 'dual-target siRNA' with Curi-Jin and Omics AI
Predicted impact: Low
Co-development agreement for a dual-target siRNA; no deal value or revenue share disclosed.
Oncocross온코크로스
382150 · KOSDAQ · ₩382150 · 온코크로스
₩3,050▼ ₩15 (0.49%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −63.43%
- Market cap
- ₩40B
- Enterprise value
- ₩26B
- P/E
- —
- P/B
- 2.9×
- Dividend yield
- 0.0%
- ROE
- −48.2%
- Net margin
- −1,653.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−79.0% from the high
₩2,235Today: ₩2,985 – ₩3,795₩14,490
Returns
- 1W−7.0%
- 1M−16.0%
- 3M−7.6%
- 6M−65.5%
- YTD−68.2%
- 1Y−62.5%
- Volume today
- 463,337
- 9.0× the 20-day average
- Traded today
- ₩1.6B
- Listed shares
- 13,046,354
- EPS (12 months)
- −₩501
- Earnings yield −16.4%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−0.5% on Oct 26, 2026. Trading value 8.3× its normal.
Oncocross says it will co-develop a dual-target siRNA, a type of drug candidate, with partners Curi-Jin and Omics AI. The headline is the only information given, so the details of the deal are unclear.
AI summary of the news and filings linked. It can be wrong; check them.
- • Foreign investors sold a net ₩59M that day
- • Buzz 73 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Buzzing- BuzzHighBuzz 73: heavy trading.
- SentimentPositiveNews: A new research partnership is a positive headline, though the sources give no financial terms. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-18.2% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Oncocross stock overview
Oncocross (온코크로스, KRX: 382150) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops AI platforms for drug discovery, centered on RAPTOR AI, which analyzes gene expression and proteomic data to match drugs with optimal indications or diseases and identify promising treatment targets. Its shares closed at ₩3,050 on Oct 26, 2026, down 0.49% on the day, giving it a market value of ₩40B.
Key facts
- Market cap
- ₩40B
- Sector
- Biotech & Pharma
- Latest price change
- −0.49%
- As of
- Oct 26, 2026
- Main business
- The company develops AI platforms for drug discovery, centered on RAPTOR AI, which analyzes gene expression and proteomic data to match drugs with optimal indications or diseases and identify promising treatment targets.
Quick answers about Oncocross
- What does Oncocross do?
- The company develops AI platforms for drug discovery, centered on RAPTOR AI, which analyzes gene expression and proteomic data to match drugs with optimal indications or diseases and identify promising treatment targets. It sells analysis services to pharmaceutical companies, including indication selection and expansion for partner drug candidates, and also offers Neo Omics proteomics analysis services, with additional cancer-focused AI tools under development.
- What is the market cap of Oncocross?
- The market capitalisation of Oncocross was ₩40B at the close on Oct 26, 2026.
- Who are the largest shareholders of Oncocross?
- According to the latest official filings, the largest reported holders are Kim Yi-rang (34.67%, as of Jun 12, 2026); Interbest (8.31%, as of Apr 23, 2025); Lee Hyun Asset Management (6.95%, as of Oct 8, 2026).
- When is the next earnings report from Oncocross?
- Korean companies rarely announce results dates in advance. Based on when Oncocross filed the same report in past years, its next 3q results is expected between Nov 7, 2026 and Nov 14, 2026.
Company profile
The company develops AI platforms for drug discovery, centered on RAPTOR AI, which analyzes gene expression and proteomic data to match drugs with optimal indications or diseases and identify promising treatment targets. It sells analysis services to pharmaceutical companies, including indication selection and expansion for partner drug candidates, and also offers Neo Omics proteomics analysis services, with additional cancer-focused AI tools under development.
Written by AI from the company's latest annual report.
- Korean name
- 온코크로스
- Sector
- Biotech & Pharma
- Themes
- ADC & cancer drugs
- CEO
- 김이랑, 강지훈 (각자대표)
- Founded
- Jun 2015
- Listed
- Dec 2024
- Listed shares
- 13,046,354
- Fiscal year ends
- Month 12
- Website
- www.oncocross.com/
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent news
Oncocross Signs Three-Way Agreement with April Bio and OmicsAI for Joint New Drug Development
Predicted impact: Low
Three-way joint drug development agreement; no financial terms disclosed.
Recent filings
See allTitles in Korean until English translations are added.
Also known as: Oncocross / 온코크로스 / 382150 / KRX:382150
Source: KRX statistical information